Eve Damiano

机构：Lindenwood University · ORCID：0009-0002-5358-4890

发表论文 6 篇 · 总被引 87 次 · h-index 4

代表论文

• The novel vasopressin receptor (V1aR) antagonist SRX246 reduces anxiety in an experimental model in humans: a randomized proof-of-concept study (2021 · Psychopharmacology · 被引 37)
• Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington’s Disease Patients—A Randomized Phase 2 Clinical Trial (2020 · Journal of Clinical Medicine · 被引 32)
• The Vasopressin 1a Receptor Antagonist SRX246 Reduces Aggressive Behavior in Huntington’s Disease (2022 · Journal of Personalized Medicine · 被引 11)
• A proof-of-concept randomized crossover clinical trial of a first-in-class vasopressin 1a receptor antagonist for PTSD: Design, methods, and recruitment (2023 · Contemporary Clinical Trials Communications · 被引 6)
• Interim Analysis Results of Buntanetap in Phase 3 Clinical Studies in Alzheimer’s and Parkinson’s Disease (2023 · Alzheimer s & Dementia · 被引 1)
• Pharmacokinetics of Novel Crystalline Buntanetap in Mice, Dogs, and Humans (2025 · Biomolecules)